Cue Biopharma, Inc. Forecast, price target & analysts
Cue Biopharma, Inc. Target price 2026 - Analyst rating & recommendation
Cue Biopharma, Inc. Classifications & Recommendation
Cue Biopharma, Inc. Price Target
| Target Price | $92.31 |
| Price | $25.57 |
| Potential |
261.01%
register free of charge
|
| Number of Estimates | 3 |
|
3 Analysts have issued a price target Cue Biopharma, Inc. 2027 .
The average Cue Biopharma, Inc. target price is $92.31.
This is
261.01%
register free of charge
$120.75
372.23%
register free of charge
$66.66
160.70%
register free of charge
|
|
| A rating was issued by 6 analysts: 5 Analysts recommend Cue Biopharma, Inc. to buy, 1 to hold and 0 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the Cue Biopharma, Inc. stock has an average upside potential 2027 of
261.01%
register free of charge
|
Sales and Margin forecast 2026, 2027 & 2028
| Dec '25 |
2026 Estimates |
|
|---|---|---|
| Revenue Million $ | 27.47 | 16.80 |
| 195.69% | 38.85% | |
| Net Margin | -96.83% | -786.46% |
| 77.88% | 712.18% |
3 Analysts have issued a sales forecast Cue Biopharma, Inc. 2026 . The average Cue Biopharma, Inc. sales estimate is
This results in the following potential growth metrics:
4 Cue Biopharma, Inc. Analysts have issued a net profit forecast 2026. The average Cue Biopharma, Inc. net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Earnings per share, P/E ratio and EV/sales Estimates 2026, 2027 & 2028
| Dec '25 |
2026 Estimates |
|
|---|---|---|
| Earnings Per Share $ | -8.43 | -25.26 |
| 61.08% | 199.64% | |
| P/E | negative | |
| EV/Sales | 10.02 |
4 Analysts have issued a Cue Biopharma, Inc. forecast for earnings per share. The average Cue Biopharma, Inc. EPS is
This results in the following potential growth metrics and future valuations:
Cue Biopharma, Inc....
Current Cue Biopharma, Inc. Upgrades & Downgrades
| Analyst | Rating | Action | Date |
|---|---|---|---|
| B. Riley Securities |
Locked
➜
Locked
|
Locked | Sep 18 2026 |
| LUCID CAPITAL MARKETS |
Locked
➜
Locked
|
Locked | Aug 25 2025 |
| Citizens Capital Markets |
Locked
➜
Locked
|
Locked | Apr 02 2025 |
| Stifel |
Locked
➜
Locked
|
Locked | Aug 20 2024 |
| Analyst Rating | Date |
|---|---|
|
Locked
B. Riley Securities:
Locked
➜
Locked
|
Sep 18 2026 |
|
Locked
LUCID CAPITAL MARKETS:
Locked
➜
Locked
|
Aug 25 2025 |
|
Locked
Citizens Capital Markets:
Locked
➜
Locked
|
Apr 02 2025 |
|
Locked
Stifel:
Locked
➜
Locked
|
Aug 20 2024 |
Discover more stocks with a high price target
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
